ADX-71149

Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 5, 2021
Post-traumatic stress disorder, Clinical trial, American depositary receipt, Cisco Webex, Research, Epilepsy, Nam, Trial of the century, Patent, Allosteric regulation, Janssen Pharmaceuticals, PAM, Glutamate (neurotransmitter), Glutamic acid, ADX-71149, Glutamate receptor, Dyskinesia, Depreciation, Lists of diseases, L-DOPA, SIX Swiss Exchange, Q&A, Nasdaq, Drug discovery, ADS, ATM, Sale, BST, GABAB receptor, CHF, Consultant, Protein, Therapy, G&A, Neurodegeneration, Blepharospasm, Lithium, Pharmaceutical industry

During the first half of 2021, income increased by CHF 0.1 million to CHF 2 million compared to the first half of 2020.

Key Points: 
  • During the first half of 2021, income increased by CHF 0.1 million to CHF 2 million compared to the first half of 2020.
  • During the second quarter of 2021, income increased by CHF 0.1 million compared to CHF 1.1 million in the second quarter of 2020.
  • During the second quarter of 2021, these expenses increased by CHF 1.4 million compared to the second quarter of 2020 primarily due to increased costs for dipraglurant PD-LID and dipraglurant blepharospasm programs.
  • During the second quarter of 2021, the net loss increased by CHF 1.6 million to CHF 4.7 million compared to the second quarter of 2020.

Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy

Retrieved on: 
Monday, June 7, 2021
Drugs, Chemical compounds, Organic compounds, ADX-71149, Chloroarenes, Lactams, Pyridines, Levetiracetam

Addex is anticipating multiple clinical study catalysts during 2021.

Key Points: 
  • Addex is anticipating multiple clinical study catalysts during 2021.
  • The first, starting with this epilepsy study, illustrates the continued commitment of our long-time collaboration partner Janssen Pharmaceuticals, Inc. to this program and to pioneering novel ways to help epilepsy patients.
  • Data from the study are expected in Q3 2022, said Tim Dyer, CEO of Addex.
  • The primary objective of the study is to evaluate the efficacy of JNJ-40411813 (ADX71149) in combination with levetiracetam using a time-to-event endpoint.

Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy

Retrieved on: 
Thursday, January 21, 2021
Drugs, Chemical compounds, Pyridines, Organic compounds, ADX-71149, Chloroarenes, Lactams, Metabotropic glutamate receptor 2, Levetiracetam, Allosteric modulator

IND approval for the mGlu2 epilepsy study is great news to start 2021 and will be the first of three clinical studies we expect to be initiate this year, said Tim Dyer, CEO of Addex.

Key Points: 
  • IND approval for the mGlu2 epilepsy study is great news to start 2021 and will be the first of three clinical studies we expect to be initiate this year, said Tim Dyer, CEO of Addex.
  • Wed like to thank the team involved for their continued support and moving quickly to get this clinical study ready for patient enrolment.
  • The primary objective of the study is to evaluate the efficacy of JNJ-40411813 (ADX71149) in combination with levetiracetam using a time-to-event endpoint.
  • Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in Q2 2021.

Addex mGlu2 PAM Program to Advance into Epilepsy Phase 2a Proof of Concept Clinical Study

Retrieved on: 
Tuesday, June 16, 2020
Organic compounds, Chemical compounds, Pyridines, ADX-71149, Chloroarenes, Lactams, Neuroscience, Metabotropic glutamate receptor 2, Janssen Pharmaceutica, Cognitive disorder, Neurocognitive, PAM

The decision of Janssen to advance ADX71149 into a Phase 2 clinical study is an exciting development and an important achievement for us, said Tim Dyer, CEO of Addex.

Key Points: 
  • The decision of Janssen to advance ADX71149 into a Phase 2 clinical study is an exciting development and an important achievement for us, said Tim Dyer, CEO of Addex.
  • Under the research collaboration and license agreement, Addex granted Janssen an exclusive worldwide license to develop and commercialize mGlu2 PAM compounds.
  • Addex's second clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for the treatment of epilepsy.
  • Preclinical programs include GABABPAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsons disease and mGlu3 PAM for neurodegenerative disorders.